BRIBF (Brii Biosciences) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)


BRIBF Brii Biosciences Ltd BRIBF
34 GF Score
Price $0.15
! 1 Warning Sign
View Full Analysis

What is Brii Biosciences LT-Debt-to-Total-Asset?

Brii Biosciences BRIBF 34 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates BRIBF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Brii Biosciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Brii Biosciences's long-term debt to total assets ratio declined from Dec. 2024 (0.01) to Dec. 2025 (0.00). It may suggest that Brii Biosciences is progressively becoming less dependent on debt to grow their business.

Brii Biosciences  (OTCPK:BRIBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Brii Biosciences LT-Debt-to-Total-Asset Related Terms

Brii Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Brii Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brii Biosciences LT-Debt-to-Total-Asset Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 0.01 0.00

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.01 0.00 0.00
BRIBF
34GF Score
Brii Biosciences Ltd BRIBF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brii Biosciences LT-Debt-to-Total-Asset Calculation

Brii Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.552/335.014
=0.00

Brii Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=0.552/335.014
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Brii Biosciences (BRIBF) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Brii Biosciences and its competitors.
Is Brii Biosciences' LT-Debt-to-Total-Asset too high?
Brii Biosciences' current LT-Debt-to-Total-Asset is 0.00. Overall, Brii Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Brii Biosciences' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Brii Biosciences and its competitors. Brii Biosciences's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (BRIBF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Brii Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Brii Biosciences (BRIBF), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brii Biosciences Business Description

Other Exchanges 02137:Hong Kong7SS:Germany
Address No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
34GF Score

Get the complete analysis for BRIBF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price